Biocon eyes $30b US insulin market via its biosimilars

With the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the US, helping it make a strong entry into that market. This also proves that the company has the science and vertical integration required to get to the US market, it said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3nolM1g
via IFTTT